KENGREAL (cangrelor)
Kengreal is a platelet inhibitor used during percutaneous coronary intervention (PCI) procedures. It helps patients who have not yet received other P2Y12 inhibitors or glycoprotein IIb/IIIa inhibitors. This medication is used to lower the risk of heart attacks during the procedure, the need for repeat revascularization, and the formation of blood clots within stents.
How KENGREAL Works
This drug works by selectively and reversibly binding to the P2Y12 platelet receptor. By targeting this specific site, it blocks ADP-induced platelet activation and aggregation. This action prevents further signaling that would otherwise lead to the formation of blood clots.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2015-06-22
- Patent Cliff
- 2035
- Routes
- INTRAVENOUS
- Dosage Forms
- POWDER
KENGREAL Approval History
What KENGREAL Treats
2 indicationsKENGREAL is approved for 2 conditions since its original approval in 2015. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Myocardial Infarction
- Stent Thrombosis
KENGREAL Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to KENGREAL
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
16 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT07225842 BIRDGE 2 | IRB202500991 | Ph 4 | recruiting | The Bridging Antiplatelet Therapy With Cangrelor 2 Study |
| NCT04667078 REPERFUSE | MMI_2020_35 | Ph 3 | recruiting | REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts |
| NCT02733341 results posted | 2015CAR77 | Ph 4 | completed | The Effect of IV Cangrelor and Oral Ticagrelor Study |
| NCT03551964 DAPT-SHOCK-AMI | 13062017-23-1 2018-002161-19 | Ph 4 | completed | Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction |
| NCT06792643 SURVIVE | SURVIVE | Ph 2 | recruiting | Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest receiVIng VA-ECMO |
| NCT04668144 SWAP-6 results posted | SMF-02 | Ph 4 | completed | Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI |
| NCT04634162 SWAP-5 results posted | SMF-01 | Ph 4 | completed | PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment |
| NCT02765633 | MDCO-CAN-15-01 2016-000134-22 | Ph 1 | completed | Cangrelor Neonatal PK/PD and Safety Study |
| NCT03247738 CANTIC results posted | IIS CHI001 WIRB | Ph 4 | completed | Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI |
| NCT03043274 results posted | 16-0990-F6A | Ph 4 | terminated | Cangrelor in ST-Elevation Myocardial Infarction to Decrease Infarct Size |
| NCT01979445 BRIDGE results posted | MDCO-CAN-13-02 | Ph 2 | completed | Cangrelor to Clopidogrel or Prasugrel Transition Study |
| NCT02978040 FABOLUS-FASTER | FABOLUS-FASTER | Ph 4 | completed | Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI. |
| NCT01852019 results posted | MDCO-CAN-13-01 | Ph 2 | completed | Cangrelor Prasugrel Transition Study |
| NCT01766466 results posted | MDCO-CAN-12-03 | Ph 2 | completed | Cangrelor Ticagrelor Transition Study |
| NCT00767507 Bridge results posted | TMC-CAN-08-02 | Ph 2 | completed | Maintenance of Platelet Inhibition With Cangrelor |
| NCT00699504 | TMC CAN 08 01 | Ph 1 | completed | Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
KENGREAL FDA Label Details
Indications & Usage
FDA Label (PDF)KENGREAL is indicated for the treatment of Myocardial Infarction; Stent Thrombosis.
Pro Intelligence Preview
Deep insights for KENGREAL
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2035
- • 7 active patents
Trial Analysis
- • 18 total trials
- • Stage: Mature
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment